Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study

BACKGROUND: The combination of BRAF and MEK inhibitors has become standard of care in the treatment of metastatic BRAF V600-mutated melanoma. Clinical factors for an early prediction of tumor response are rare. The present study investigated the association between the development of an early exanth...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Front Oncol
Main Authors: Kähler, Katharina C., Gutzmer, Ralf, Meier, Friedegrund, Zimmer, Lisa, Heppt, Markus, Gesierich, Anja, Thoms, Kai-Martin, Utikal, Jochen, Hassel, Jessica C., Loquai, Carmen, Pföhler, Claudia, Heinzerling, Lucie, Kaatz, Martin, Göppner, Daniela, Pflugfelder, Annette, Bohne, Ann-Sophie, Satzger, Imke, Reinhardt, Lydia, Placke, Jan-Malte, Schadendorf, Dirk, Ugurel, Selma
Formato: Artigo
Idioma:Inglês
Publicado em: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8183381/
https://ncbi.nlm.nih.gov/pubmed/34109122
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2021.672172
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados